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Abstract To current knowledge, transforming growth factor L
(TGFL) signaling is mandatory to establish liver fibrosis and
various molecular interventions designed to affect the TGFL
system were successfully used to inhibit fibrogenesis. Activated
hepatic stellate cells (HSC), which are one important source of
TGFL, are the major producers of extracellular matrix proteins
in liver injury. We have previously shown that the TGFL response
of this cell type is modulated during the transdifferentiation
process. This work delineates the activation of TGFL down-
stream mediators, the Smads, in quiescent HSC and transdiffer-
entiated myofibroblasts (MFB). The expression level of all
Smads remained largely unchanged during this process. The
response of HSC to TGFL, leading to, e.g., induction of K2 (I)
collagen expression, is mediated by phosphorylation of Smad2
and Smad3 and subsequent nuclear translocation of a Smad
containing complex. Neither TGFL-dependent nor endogenously
phosphorylated Smad2/3 was detectable in comparable amounts
in transdifferentiated MFB, indicating loss of TGFL sensitivity.
Ectopic expression of Smad7 in HSC led to inhibition of Smad2
phosphorylation and abrogated TGFL response. In transdiffer-
entiated MFB, expression of a constitutively active TGFL
receptor I, but not treatment with TGFL1, resulted in transcrip-
tional activation of a TGFL responsive promoter, thereby
demonstrating completely restored TGFL signal transduction.
Our data indicate that in contrast to a postulated mechanism of
enduring autocrine TGFL signal transduction, early and late
stages of HSC activation have to be distinguished, which is of
importance for antifibrotic therapies. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Members of the transforming growth factor L (TGFL) fam-
ily of peptide growth factors, which include TGFL, bone mor-
phogenetic proteins and activins, regulate a broad range of
cellular processes, reaching from cell growth and di¡erentia-
tion to apoptosis [1^3]. The signaling responses to TGFL and
other family members are mediated by a heteromeric complex
of two types of transmembrane serine/threonine kinase recep-
tors at the cell surface and their intracellular substrates, the
Smad proteins [1^4]. Following ligand binding, the type II
receptor kinases phosphorylate and thereby activate the type
I receptor cytoplasmic domains. The Smads then act as type I
receptor-activated signaling e¡ectors, which, following recep-
tor-induced phosphorylation, move into the nucleus to acti-
vate transcription of a select set of target genes [5,6].
TGFL is thought to be an important cytokine in the regu-
lation of the production, degradation, and accumulation of
extracellular matrix (ECM) proteins, and it may play a pivotal
role in ¢broproliferative changes that occur following tissue
damage in liver ¢brosis. TGFL is synthesized by several mes-
enchymal liver cells and is also released by hepatocytes [7] and
generated by in¢ltrating cells such as lymphocytes, monocytes/
macrophages, and platelets. Following injury or in£amma-
tion, all these cells are potential sources of TGFL.
In liver, hepatic stellate cells (HSC), comprising 15% of the
total number of resident cells, are the key ¢brogenic progen-
itor cell type [8,9]. In normal liver, they are the principal
storage site for retinoids [10]. Subsequent to liver injury,
HSC undergo a process known as activation, which is the
transition of quiescent cells into proliferative, ¢brogenic, and
contractile myo¢broblasts (MFB). Characteristic features of
activated HSC are a variety of interactions with hepatocytes,
endothelial cells, Kup¡er cells and in£ammatory phagocytes
[11^13], involving cytokines, chemokines [14,15], oxidants
[16], and products of ECM [17]. The potential pro¢brogenic
role of TGFL has been impressively shown in numerous de-
scriptive studies and in experimental models [18^20]. These
¢ndings, together with TGFL’s ability to regulate the expres-
sion of many ECM protein genes, and its increased expression
and release during activation of HSC, have led to a widely
accepted model, in which autocrine stimulation of MFB by
0014-5793 / 01 / $20.00 ß 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 6 5 6 - 4
*Corresponding author. Fax: (49)-241-8888 512.
E-mail address: steven.dooley@post.rwth-aachen.de (S. Dooley).
Abbreviations: BDL, bile duct ligation; CA, constitutive active;
DMEM, Dulbecco’s modi¢ed Eagle medium; ECM, extracellular
matrix; FCS, fetal calf serum; HSC, hepatic stellate cell(s); MFB,
myo¢broblast(s); TBS, Tris-bu¡ered saline; TGFL, transforming
growth factor L ; TLRI, TGFL receptor type I; TLRII, TGFL
receptor type II
FEBS 25067 23-7-01 Cyaan Magenta Geel Zwart
FEBS 25067FEBS Letters 502 (2001) 4^10
endogenously produced TGFL is the dominant stimulus of
¢brogenic ECM production and perpetuation in diseased liv-
er. In contrast to this, we have previously shown that quies-
cent HSC, activated HSC and MFB behave di¡erently to
treatment with TGFL1 [21]. In quiescent HSC, addition of
TGFL1 resulted in proliferation inhibition, transcriptional in-
duction of di¡erent TGFL target genes, hyaluronan release
and formation of Smad binding element interacting com-
plexes. In contrast, transdi¡erentiated MFB were at least par-
tially resistant to the aforementioned TGFL e¡ects. TGFL
receptor types I and II (TLRI and TLRII) were expressed
with similar transcript amounts in both cell types. However,
strongly reduced radiolabeled ligand binding activity to sur-
face receptors was detected in MFB, suggesting modulation of
TGFL responsiveness during activation and transdi¡erentia-
tion of HSC.
In recent years, anti¢brotic strategies, based on a general
suppression of TGFL signaling, have been developed. How-
ever, due to many essential roles of TGFL in important cel-
lular processes, anti-TGFL therapies have to be carefully fo-
cused to speci¢c cell types and physiological stages. Therefore,
it is important to get further insight into the role of TGFL in
di¡erent stages of HSC activation during liver ¢brogenesis. In
the current report, we have analyzed molecular details of in-
tracellular TGFL signaling to the nucleus comparatively in
HSC and MFB. Based on our ¢ndings with primary cultured
cells, we suggest a re¢ned model of pro¢brogenic TGFL signal
transduction, in which transdi¡erentiated HSC become parti-
ally TGFL insensitive.
2. Materials and methods
2.1. Materials
Restriction enzymes and modifying enzymes (T4 DNA ligase, Kle-
now fragment of DNA polymerase I) were purchased from Roche or
Gibco-BRL. Taq polymerase and [K-32P]dCTP were from Amersham/
Pharmacia. All reagents for cell culture (Dulbecco’s modi¢ed Eagle
medium (DMEM), fetal calf serum (FCS), trypsin-EDTA and phos-
phate-bu¡ered saline) were from Gibco-BRL. The monoclonal anti-
Flag antibody was from Sigma (M5, F-4042). Oligonucleotides were
from MWG Biotech or Genset. The transfection reagent Fugene-6
was from Roche. The luciferase assay system was from Promega.
Antisera for Smad2, 3, 4 and 7 were raised against the peptides de-
scribed in [22] or purchased from Santa Cruz Biotechnology or
Zymed Laboratories Inc., as indicated. The anti-mouse horseradish
peroxidase-conjugated secondary antibody was from Santa Cruz or
Zymed. All other chemicals were obtained from commercial sources at
the purest grade available.
2.2. Experimental induction of ¢brosis in rats
Male Sprague^Dawley rats (about 300 g body weight) were pur-
chased from Harlan-Winkelmann. The animals were kept in a temper-
ature-controlled environment (22‡C) with a 12 h light^dark cycle and
fed ad libitum with standard rat chow. Animals had free access to tap
water. HSC were isolated from bile duct ligated (BDL) rats as de-
scribed below. Before each procedure, animals were anesthetized with
100 mg/kg ketamine (Sano¢-ZEVA) and 50 Wl 2% Rompun (Bayer)
intraperitoneally. Study protocols were performed in compliance with
the institution guidelines. Experiments were performed after an over-
night fast. BDL was performed as previously described [23,24].
Brie£y, the common bile duct was located through a midline incision
and double ligated near the liver hilus with transection between the
ligatures. Controls underwent a sham operation that consisted of ex-
posure, but no ligation of the common bile duct.
2.3. Preparation of cells
Isolation and culture of liver HSC from male Sprague^Dawley rats
(500^600 g body weight) were performed as described previously
[25,26]. All animals received human care in compliance with the Ger-
man Animal Protection Act, which is in accordance with the National
Research Council’s criteria. In brief, non-parenchymal liver cells were
isolated by the pronase-collagenase method. HSC were puri¢ed by a
single-step density gradient centrifugation with Nycodenz (8.1%; w/v)
in Hank’s balanced salt solution without NaCl (Nyegaard Co. AS,
Oslo, Norway) and identi¢ed by their typical light-microscopic ap-
pearance and vitamin A-speci¢c auto£uorescence. The mean purity
of freshly isolated cells was 85^95%, cell viability was 95%, and the
yield ranged from 20 to 40U106 cells/liver. HSC were seeded with
densities of 0.2U106 cells/10 cm2 for immunostainings and 3U106
in a 75 cm2 £ask for metabolic labeling or RNA preparations. They
were cultured in DMEM supplemented with 4 mmol/l L-glutamine,
10% FCS, 100 IU/ml penicillin, and 100 mg/ml streptomycin at 37‡C
in a humidi¢ed atmosphere of 5% CO2 and 95% air. The ¢rst change
of medium was made approximately 20 h after seeding, after which
the purity of HSC was 97%. The second change of medium was done
about 18 h later, during which FCS supplementation was reduced to
0.5%. MFB were obtained by secondary culture of 7 day old HSC,
and cells were kept in general for 48 h after initiation of secondary
culture. Cultured HSC were checked for contaminating endothelial
cells and Kup¡er cells with diacetylated low-density lipoprotein (Har-
bor Bioproducts) and Fluoresbrite latex beads (1 mm; Polysciences
Inc.), respectively. HEK293 human embryonic kidney carcinoma cells
were cultured in DMEM, 4 mM L-glutamine, including 10% FCS.
Additionally, all culture media were supplemented with penicillin
(100 IU/ml)/streptomycin (100 Wg/ml). All cultures were maintained
at 37‡C, 5% CO2 in a humidi¢ed atmosphere.
2.4. Preparation of total cell lysate, nuclear extracts and immunoblot
analysis
Total lysates from 64 mm2 cell culture plates were prepared with 0.9
ml RIPA bu¡er (1UTris-bu¡ered saline (TBS), 1% Nonidet P-40
(Amresco), 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate
(SDS)); protease inhibitors were provided as Protease Inhibitor Mix
(Roche) just before use: for preparation of nuclear extracts, 10 Wl/ml
PMSF (10 mg/ml in isopropanol) and 10 Wl/ml 100 mM sodium or-
thovanadate were added. To inhibit protein dephosphorylation, Phos-
phatase Inhibitor Mix (Sigma) was added. Using a syringe ¢tted with
a 21 gauge needle to shear DNA, lysates were transferred to a micro-
centrifuge tube. 10 Wl of a 10 mg/ml PMSF stock was added followed
by a 30^60 min incubation on ice. Subsequently, cell lysates were
cleared by centrifugation at 15 000Ug for 20 min at 4‡C. For nuclear
extract preparation, cells were harvested and processed according to
the protocol of Dennler et al. [27] with minor modi¢cations. Brie£y,
con£uent cells from four dishes (100 mm2) were washed with TBS and
scraped. After another washing, cells were suspended in 400 Wl/dish of
ice cold bu¡er A (10 mM HEPES-KOH pH 7.9, 1 mM Na3VO4, 0.5
mM dithiothreitol (DTT), 1.5 mM MgCl2, 10 mM KCl, 0.2 mM
PMSF). The cells were allowed to swell on ice for 10 min and then
lysed by 30 strokes of a Dounce all glass homogenizer. Nuclei were
pelleted by centrifugation and resuspended in 50 Wl/dish of ice cold
bu¡er C (20 mM HEPES pH 7.9, 20 mM NaF, 1 mM Na3VO4, 1 mM
Na4P2O7, 0.13 WM okadaic acid, 1 mM EDTA, 1 mM EGTA, 0.4
mM ammonium molybdate, 420 mM NaCl, 20% glycerol, 1 mM
DTT, 0.5 mM PMSF and 1 Wg/ml each leupeptin, aprotinin and
pepstatin). At this step Phosphatase Inhibitor Mix (Sigma) was added.
The nucleus membrane was lysed by 15 strokes of a Dounce all glass
homogenizer. The resulting suspension was stirred for 30 min at 4‡C.
The clear supernatant was aliquoted and frozen at 380‡C.
40 Wl of lysates or nuclear extracts were separated by SDS^8%
polyacrylamide gel electrophoresis (PAGE) and transferred to a 0.45
Wm nitrocellulose membrane (Protran BA 85; SchleicherpSchu«ll).
Non-speci¢c binding was blocked by 5% non-fat milk powder in
TBS overnight at 4‡C followed by incubation with the primary anti-
bodies (diluted 1:2000 in 2.5% non-fat milk powder in TBS for 1 h at
room temperature). Blots were washed two times in TBS/0.05%
Tween-20 (Bio-Rad, Munich, Germany) and subsequently three times
in TBS for 5^10 min each. The secondary antibody anti-rabbit horse-
radish peroxidase (stock solution: 400 Wg/ml; Santa Cruz Biotechnol-
ogy Inc.) was incubated at a dilution of 1:50 000 for an additional
hour at room temperature followed by ¢ve washes as described above.
Bound antibodies were detected by developing the membrane in
Supersignal Ultra (Pierce) for 5 min and subsequent evaluation with
a Lumi Imager (Roche). Speci¢c antisera against Smad2, Smad3,
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Smad4 and Smad7 were described in [22] or purchased by Santa Cruz
Biotechnology Inc. and Zymed as indicated. The antiserum PS2,
which was raised against the phosphorylated synthetic peptide
SS(P)MS(P) as previously described [28], was used to detect phosphor-
ylated Smad2. The antiserum recognizing phosphorylated Smad1 [28]
crossreacts with phosphorylated Smad3 and was used to detect Smad3
activation. As a control for speci¢city and to facilitate identi¢cation of
the protein of interest, detection was performed in the absence or the
presence of the peptide, to which each of the antisera was originally
raised. Furthermore, extracts of cells ectopically expressing Flag-
tagged Smad proteins were used as positive controls in Western blots.
Their expression was checked before by an anti-Flag antibody (Sig-
ma).
2.5. Immunostainings
Immunostainings of HSC were performed using an immuno£uores-
cence method. TGFL-treated HSC or MFB and untreated controls
were seeded on glass precoated with FCS in six well plates. The cells
were washed three times with TBS and ¢xed with 4% (w/v) paraform-
aldehyde in TBS for 15 min at room temperature. After ¢xation, cells
were rinsed with TBS and then permeabilized with 0.1% (v/v) Triton
X-100 plus 0.1% (w/v) sodium citrate for 2 min on ice. Unspeci¢c
binding sites were blocked with 50% (v/v) FCS in TBS plus 0.1%
(w/v) bovine serum albumin (BSA). Cells were then incubated for
2 h at room temperature with the polyclonal anti-PS2 serum (1:500)
in TBS plus 0.1% BSA. After extensive washing (¢ve times with TBS),
the appropriate £uorochrome-linked secondary antibody (Cy3-conju-
gated anti-rabbit IgG, Zymed 62-6115) was added for 1 h. Finally,
cells were washed three times in TBS, one time in H2O and embedded
in antifade. Staining was documented by an LSM 510 Laser Scanning
Microscope (Zeiss).
2.6. Adenoviral infections
Adenoviral stocks for (CAGA)9-MLP-Luc were obtained using the
Adeasy cloning and recombination procedure (Quantum, Appligene,
www.quantum-appligene.com) and infections were performed as de-
scribed previously [29]. Under optimal conditions, more than 90% of
HSC and MFB were infected as determined by the green £uorescent
auto£uorescence of an adenoviral green £uorescent protein (GFP)
construct. Routine infections were performed at a multiplicity of in-
fection (m.o.i.) of 50 with single virus clones. After infection, cells
were cultured for 2 days in DMEM with 10% FCS, serum-starved
for 8 h with medium containing 0.5% FCS and stimulated with 5 ng/
ml TGFL1. Lysates for luciferase detection were prepared 14 h later.
Adenoviral stocks for constitutively active TLRI (CA-TLRI) and
Smad7 were kindly provided by A. Moustakas, Ludwig Institute for
Cancer Research, Uppsala, Sweden.
3. Results
3.1. Activation of HSC and transdi¡erentiation to MFB
Freshly prepared, highly puri¢ed rat HSC were seeded on
uncoated plastic. In an early and quiescent state, HSC showed
perinuclear droplets, containing vitamin A. During growth,
the cells became spontaneously activated and developed fea-
tures of ¢brogenically activated HSC (Fig. 1). The morpho-
logical changes of transdi¡erentiated HSC, here termed MFB,
are preceded by, e.g., increased expression of collagen,
K-smooth muscle actin, and TGFL [30]. We have investigated
these known biochemical markers to con¢rm ¢brogenesis like
progression of in vitro cultured HSC. The expression of
K-smooth muscle actin and TGFL1 increased during ongoing
activation (data not shown), supporting the widely accepted
paradigm of HSC activation, including autocrine TGFL sig-
naling as key event of ECM production and ¢brogenesis.
After 7 days, activated HSC were passaged and subsequently
displayed the fully transdi¡erentiated phenotype (MFB, Fig.
1). We found that HSC- and MFB-produced TGFL in con-
ditioned medium was present almost entirely in the latent and
not in its active form (data not shown). Therefore, we used
overnight serum starvation and subsequent addition of active
TGFL1 into the medium to test TGFL responsiveness in HSC
and in MFB.
3.2. TGFL signal transduction by activation of Smad2
To study intracellular TGFL signal transduction, we ana-
lyzed activation of endogenously expressed Smad2 using an
antiserum speci¢cally detecting phosphorylated Smad2 (Fig.
2). In HSC, an impressive TGFL-dependent increase in
Smad2 phosphorylation occurred. MFB, in contrast, did not
respond to TGFL1 with an elevated P-Smad2 band. Further-
more, Smad2 was not constitutively phosphorylated in MFB
Fig. 1. Phenotypic features of HSC activation. During cultivation of HSC in plastic dishes, cells become spontaneously activated and transdif-
ferentiate from quiescent vitamin A storing cells to proliferative ¢brogenic MFB, thereby representing a cell culture model of liver ¢brogenesis.
Early molecular markers of HSC activation are TGFL1 and K-smooth muscle actin expression, followed by induction of ECM genes. The re-
sulting phenotypic changes, which characterize MFB, are indicated.
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(at least not in amounts comparable to stimulated HSC),
which would be expected as intermediate of autocrine stimu-
lation by endogenously produced TGFL. Phosphorylated
Smad2 was also investigated in nuclear extracts from 2 and
7 day old HSC, transdi¡erentiated MFB and from activated
HSC, which were isolated from experimentally induced ¢-
brotic rat liver (MFB*). The results re£ect the data from total
cell lysate. Two day old HSC respond stronger to TGFL1
than 7 day old HSC. MFB, cultured subsequent isolation
from BDL rats, displayed a slightly increased P-Smad2 band
compared to in vitro transdi¡erentiated MFB. Activated
Smad2 forms heterodimeric complexes with Smad4 or hetero-
trimeric complexes with Smad3 and Smad4, which were trans-
located into the nucleus, where they function as regulators of
target gene transcription. We studied nuclear translocation of
activated Smad complexes in 3 day old HSC and MFB, in the
presence and absence of TGFL1 by immunohistochemistry
(Fig. 3). As expected from Western blot data, strong TGFL-
dependent nuclear staining occurred in HSC. TGFL1-treated
MFB displayed a similar background staining as untreated
controls. No cytoplasmic staining was observed, con¢rming
that only the phosphorylated form of Smad2 is detected e⁄-
ciently with anti-PS2. Treatment of anti-PS2 serum with the
peptide, against which the serum was raised, prior to immu-
nostaining as a control resulted in cells without £uorescent
staining (data not shown).
3.3. Proteasome degradation of activated Smad2
One possibility to explain reduced P-Smad2 staining in
MFB is a diminished lifetime of the activated protein. It has
been shown previously that following receptor-mediated acti-
vation of Smad2, multi ubiquitination and subsequent degra-
dation of Smad2 by the proteasome occur [31,32]. In 2 day
old HSC, maximal amounts of P-Smad2 were detectable 1 h
after TGFL treatment, which declined thereafter to back-
ground levels (data not shown). To exclude an accelerated
P-Smad2 degradation mechanism to be responsible for the
absence of a TGFL-dependent increase of P-Smad2 in MFB,
we treated the cells with two di¡erent 26S proteasome inhib-
itors, MG-132 and lactacystin (Fig. 4). Both inhibitors had
the potential to extend the lifetime of phosphorylated Smad2
in HSC, similarly as previously shown for several other cell
types (HaCaT, COS-1, HepG2, HeLa, EpH4, EpRas; [31,32]).
Six hours after treatment of MFB with TGFL1, the faint
band, which was detectable with similar intensities in un-
treated and TGFL-treated MFB (see Figs. 2 and 4, lanes 1^
4), is further decreased below this basal level (Fig. 4, lane 5).
Addition of lactacystin or MG-132 for 6 h led to conservation
of this weak P-Smad2 signal (Fig. 4, lanes 6 and 7), suggesting
that a basal TGFL-Smad2 signaling is present in MFB, which
Fig. 2. Analysis of TGFL1-induced Smad2 phosphorylation in HSC
and MFB. Cells were grown to con£uence and serum-starved over-
night with 0.5% FCS, followed by stimulation with 5 ng/ml TGFL1
(+). As controls, untreated cells were analyzed (3). Cell lysates were
prepared from whole cells or from isolated nuclei, as indicated, ana-
lyzed by SDS^PAGE, followed by Western blotting and immunode-
tection using a speci¢c antiserum against phosphorylated Smad2
(PS2). Parallel blots were probed in the presence of blocking pep-
tides, to which the PS2 antiserum was originally raised, resulting in
blank lanes (not shown), or with a Smad2-speci¢c antibody, to con-
¢rm equal protein expression. The position of the P-Smad2 band is
indicated by the arrow. MFB* indicates lysate from primary cul-
tured activated HSC, which were isolated from BDL ¢brotic rats.
The results are representative for at least three independent experi-
ments.
Fig. 3. TGFL1-dependent nuclear translocation of phosphorylated Smad2 in HSC. Three day old HSC and transdi¡erentiated MFB were sub-
jected to immunostaining with an antiserum against phosphorylated Smad2 (PS2) and subsequent analysis by laser scanning microscopy.
TGFL1-treated HSC display a strong nuclear staining, which is absent in TGFL1-treated MFB and untreated controls. TGFL1-treated HSC,
which were probed in the presence of blocking peptides to which the PS2 antiserum was originally raised, were used as a negative control (not
shown).
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however is far below the amount in stimulated HSC. These
data indicate that reduced TGFL signal transduction via
Smad2 instead of a more rapid degradation of P-Smad2 takes
place in MFB.
3.4. Lack of Smad3 phosphorylation in MFB
To investigate Smad3 activation in HSC and MFB, we used
an antiserum, PS1, which was raised against a phosphorylated
C-terminal peptide of Smad1 and which displays crossreactiv-
ity with phosphorylated Smad3. Due to a faster mobility of
Smad3 in PAGE, it can be easily di¡erentiated between
P-Smad1 and P-Smad3. Similar to our ¢ndings concerning
Smad2, HSC showed signi¢cant TGFL-dependent Smad3
phosphorylation. Like Smad2, Smad3 as well is not activated
in MFB, neither by treatment with TGFL1 nor constitutively
as a result of a suggested autocrine stimulation (Fig. 5). This
suggests that loss of TGFL-dependent Smad phosphorylation
during ¢brogenic progression of HSC is not restricted to a
Smad2 containing pathway, but a¡ects Smad3 as well.
3.5. Ectopic expression of Smad7 and CA-TLRI in HSC and
MFB leads to inhibition/restoration of TGFL signaling,
respectively
To further investigate TGFL e¡ects on HSC and MFB, we
used a very sensitive TGFL reporter construct, (CAGA)9-
MLP-Luc, containing exclusively nine copies of the Smad
binding site, derived from the PAI-1 promoter. (CAGA)9-
MLP-Luc was shown to confer a several hundred-fold
TGFL-mediated luciferase induction in HepG2, Mv1Lu and
NIH3T3 cells. To improve introduction of the construct in
HSC and MFB, we generated adenoviruses containing
(CAGA)9-MLP-Luc. Adenovirus-mediated gene transfer is
very e⁄cient (80^95% infection rate), and high expression
levels of encoded proteins were obtained. In di¡erent prepa-
rations of HSC, luciferase activity was stimulated between
3- and 10-fold, depending on the activation stage of the cells
(Fig. 6A and data not shown). In contrast, MFB did not
respond to TGFL1 and no stimulation of the reporter gene
was observed (Fig. 6B).
To stimulate the TGFL pathway in MFB, we next utilized
an adenoviral vector encoding the CA-TLRI (also termed ac-
tivin receptor like kinase 5). In HSC, expression of CA-TLRI,
similarly as treatment of the cells with TGFL1, led to Smad2
phosphorylation and activation of a coinfected (CAGA)9-
MLP-Luc containing virus (Fig. 6A). Additional infection
with an adenovirus encoding Smad7 inhibited CA-TLRI sig-
nal transduction. In MFB, in contrast to TGFL1 treatment,
expression of CA-TLRI resulted in Smad2 phosphorylation
and (CAGA)-box stimulation, comparable to HSC (Fig.
6B). Again, Smad7 was able to antagonize this e¡ect.
4. Discussion
In cirrhotic liver, HSC are responsible for increased pro-
duction and deposition of ECM. Activation of HSC in vivo
and in culture includes, e.g., increased expression of type I
collagen, expression of cytoskeletal markers like K-smooth
muscle actin, and increased proliferation [10,30,33]. After liver
injury, HSC rapidly are induced to express and secrete TGFL.
The detailed role of TGFL signal transduction during di¡erent
stages of HSC transdi¡erentiation remains to be identi¢ed.
Critical downstream targets of TGFL signal transduction are
type II and type I receptors and members of the Smad family.
In a recent paper [21], we have compared the e¡ect of TGFL
in di¡erent stages of HSC activation and found striking di¡er-
ences between quiescent HSC and transdi¡erentiated MFB.
Whereas HSC display typical TGFL-dependent proliferation
inhibition and target gene activation, MFB did not respond.
Both receptors were expressed with similar amounts in HSC
and MFB. However, ligand binding to TGFL receptors was
strongly decreased in transdi¡erentiated MFB compared to
HSC. In contrast to this, it was reported that isolated HSC
from CCl4-treated rats displayed constant surface expression
Fig. 4. Proteasome degradation of phosphorylated Smad2 in 3 day
old HSC and in MFB. All lysates were analyzed by immunoblotting
using the antibody speci¢c to C-terminally phosphorylated Smad2
(PS2). Upon continuous TGFL1 stimulation in HSC, the level of
phosphorylated Smad2 peaks at about 1 h and declines thereafter,
reaching background staining after 6 h. The proteasome inhibitors
MG-132 and lactacystin block time-dependent loss of Smad2 phos-
phorylation. Both proteasome inhibitors did not display remarkable
e¡ects on P-Smad2 availability in MFB preparations.
Fig. 5. Analysis of TGFL1-induced Smad3 phosphorylation in HSC
and MFB. Protein extracts as described in Fig. 2 were used. Immu-
nodetection was performed using an antiserum, which was originally
raised to detect phosphorylated Smad1 (PS1). This antiserum dis-
plays crossreactivity with phosphorylated Smad3, which has a faster
mobility during PAGE than Smad1 and Smad2. To con¢rm Smad3
speci¢city of the bands, a parallel blot of Flag-tagged Smad3 ex-
pressing HEK293 cells was probed with an anti-Flag antibody. The
position of the P-Smad3 band is indicated by the arrow. The blot
was reprobed with a Smad3-speci¢c antibody to con¢rm equal ex-
pression (lower panel).
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of all TGFL receptors [34], suggesting possible di¡erences in
the transdi¡erentiation mechanisms in spontaneous or liga-
tion-induced versus CCl4-induced HSC activation. A possible
explanation for reduced binding of recombinant TGFL1 to
surface receptors in MFB may be high level autocrine signal-
ing of endogenously synthesized TGFL. Therefore, we focused
our advertence to TGFL downstream signaling and examined
the activation of Smads in di¡erent stages of HSC activation.
Smad expression was largely unchanged during in vitro acti-
vation of HSC (data not shown). Rapid TGFL1-dependent
phosphorylation of Smad2 was present in quiescent HSC (2
days cultured), decreased during activation and was absent in
fully transdi¡erentiated MFB. MFB, isolated from BDL rat
liver, similarly did not show signi¢cant Smad2 phosphoryla-
tion. These data were con¢rmed by examining TGFL-depen-
dent transport of activated Smad complexes into the nucleus,
which was found exclusively in HSC. To detect possible di¡er-
ences in the turnover rate of activated Smad2, we investigated
its proteasome degradation as previously described [31]. The
results, displaying only a minimal in£uence of two di¡erent
proteasome inhibitors on the availability of phosphorylated
Smad2 in MFB, further suggested that a strongly reduced
signaling via Smad2 is present in transdi¡erentiated cells.
The faint P-Smad2 band preserved from degradation in
MFB may be based on the presence of a few cells, that are
not fully transdi¡erentiated and therefore are still reactive to
TGFL or alternatively to a residual sensitivity of MFB.
Besides Smad2, TGFL may use Smad3 or a di¡erent signal-
ing cascade involving mitogen-activated protein kinase path-
ways to transmit an intracellular signal. To investigate the
Smad pathway more generally, we infected HSC and MFB
with adenoviruses containing (CAGA)9-MLP-Luc, which re-
cruits activated Smad3 and/or Smad4 containing complexes.
Signi¢cant TGFL1-dependent reporter gene activation in HSC
was shown, which was completely absent in MFB. Smad-de-
pendent TGFL insensitivity was further con¢rmed by experi-
ments, showing lack of TGFL-dependent or constitutive
Smad3 activation in MFB.
Substantiated by these results, we have developed a work-
ing hypothesis, which is di¡erent from the widely suggested
model of liver ¢brosis, based on continuous autocrine ¢bro-
genic stimulation of transdi¡erentiated MFB by endogenously
produced TGFL. We propose that TGFL action is an impor-
tant early and initiating step during HSC activation. Quies-
cent HSC are very sensitive for TGFL and transmit intracel-
lular signals to the nucleus, where numerous genes involved in
HSC activation and/or ECM protein expression, including e.g.
collagen, are the targets. TGFL-dependent transdi¡erentiation
leads to phenotypic changes, which include TGFL-indepen-
dent ECM synthesis [35^38] and loss of TGFL-dependent
growth control as well as Smad-dependent signal transduc-
tion.
TGFL insensitivity of MFB does not seem to be based on
high levels of endogenous TGFL expression and secretion,
since 3 day old HSC, which are able to transmit a clearly
detectable TGFL signal, produce similarly high amounts of
TGFL as MFB, which are insensitive. TGFL receptor surface
downregulation/internalization seems to be an important sub-
ject involved in reduced TGFL signal transduction in MFB.
FKBP12 has recently been reported as a negative regulator of
TGFL receptor internalization [39] and its role in HSC during
¢brogenesis has not yet been investigated. Furthermore, in
line with our ¢nding that TGFL receptor protein expression
was high in MFB, but surface localization was low, Zwaagstra
et al. have shown a predominant intracellular localization of
TLRI and its increased nuclear accumulation after growth
arrest in Mv1Lu and A549 cells [40,41]. Preliminary data
show a similar nuclear staining for TLRI in HSC and MFB,
and we currently use an adenoviral TLRII^GFP fusion con-
struct to identify its subcellular localization in HSC and MFB.
In various experimental models, it was impressively shown
that anti-TGFL therapeutic strategies are able to signi¢cantly
reduce or abolish ¢brogenesis or ongoing ¢brosis [18^20]. Ec-
topic expression of Smad7 led to a block of TGFL signal
transduction in HSC and therefore may be a further potential
anti¢brotic agent, more speci¢cally interrupting Smad-depen-
dent signaling. By expression of a constitutively activated
TLRI, we were able to restore TGFL signaling in MFB, which
Fig. 6. Modulation of TGFL signal transduction by ectopic expres-
sion of Smad7 and CA-TLRI in HSC and MFB. HSC (A) and
MFB (B) were infected with adenoviruses carrying CA forms of
TLRI, Smad7 and a (CAGA)9-MLP-Luc reporter DNA at an m.o.i.
of 50 each. Expression of TLRI and Smad7 proteins was con¢rmed
by Western blot experiments using speci¢c antibodies as described
in Section 2 and in [28]. The e¡ect of protein expression on TGFL
signal transduction was measured by PS2 immunoblot and
(CAGA)9-MLP-Luc reporter gene analysis. For TGFL-dependent
(CAGA)9-MLP-Luc stimulation, cells were serum-starved for 8 h
with 0.5% FCS prior to addition of TGFL1, and subjected to lysate
preparation 14 h later. The presented data are representative for at
least three independent investigations.
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also may have therapeutic consequences with respect to its
proliferation inhibitory e¡ect.
In summary, our data display that fully transdi¡erentiated
MFB are almost insensitive to TGFL, mainly shown by the
lack of Smad activation. As a consequence, the pro¢brogenic
e¡ect of TGFL, produced in and secreted from MFB, may be
paracrine and may target to the environment, thereby activat-
ing neighboring quiescent HSC and inducing apoptosis in he-
patocytes. In a homeostatic stage, this contributes to wound
healing and tissue repair. In a deregulated stage with excess
TGFL, this may lead to reduced hepatocyte regeneration, pro-
liferation of activated HSC and ¢nally ¢brogenesis.
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